Monitor for any future conversion to a 13D filing, which would signal activist intent. The increase by a passive holder is routine, but the size (7.3%) gives Farallon significant influence if it chooses to engage.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $78.17entry
- T+1 · 4d ago +0.17%α +0.53% · $78.30
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Farallon Capital Management filed an amended Schedule 13G disclosing a 7.3% passive stake in BridgeBio Pharma as of September 30, 2026, up from 5.1% reported by BlackRock in late October. The increase adds approximately 4.6 million shares, reflecting continued accumulation by a major institutional investor.
Key Financial Metrics
Key Facts
- Farallon Capital Management now holds 14,247,000 shares of BridgeBio Pharma common stock, representing 7.3% of shares outstanding as of September 30, 2026.
- This is an amendment to a prior Schedule 13G, indicating an increase from the previously disclosed stake.
- The filing is passive (Rule 13d-1(b)), with no intent to influence control of the company.
- Shares are held through eight Farallon investment partnerships.
Financial Impact
Stake increased to 7.3% from a prior level; at the $15.2B market cap, the stake is valued at approximately $1.11B.
Risk Factors
- Passive filing status could change if Farallon later engages with management or seeks board representation.
- No indication of activist intent at this time.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000908834-26-000518 |
| Document: 0000908834-26-000518-index.html | 0000908834-26-000518 |
| Document: 0000908834-26-000518.txt | 0000908834-26-000518 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Viewing Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers